Delay of more than 42 days for breast cancer surgery raises death risk for certain subtypes, study finds
Patients with certain subtypes of breast cancer may face a higher risk of death from the cancer if they wait more than 42 ...
Genetically modified natural killer cells show promise in cancer immunotherapy
Among other functions, the NK cells (natural killers, a type of lymphocyte forming part of the immune system) have the capacity to detect and eliminate cancer cells. But in some cases they cannot ...
Oncology Nursing News11h
Patient Education Is Key to Improve Patient Adherence to Cancer Treatment
BC, OCN, explained that comprehensive disease and treatment education are essential to adherence for patients with breast ...
News-Medical.Net on MSN13h
Researchers develop tool to enhance NK cells against cancer
A team of researchers from the Hospital del Mar Research Institute, the Universitat Autònoma de Barcelona and the Pompeu Fabra University has developed a new tool that allows modifying these NK cells ...
Applied Clinical Trials Online15h
VERITAC-2 Trial Shows Vepdegestrant Significantly Improves Survival in ESR1-Mutant Breast Cancer
Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant ...
Gastroenterology Advisor15h
FDA Grants Traditional Approval to Keytruda for HER2+ Gastric/GEJ Cancer
The FDA has granted traditional approval to Keytruda (pembrolizumab) in combination with trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma.
Innovent Biologics: Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian Cancer
SAN FRANCISCO and SUZHOU, China, March 23, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that ...